← Back to Search

Beta-3 Adrenergic Receptor Agonist

Mirabegron for Type 2 Diabetes (GB9 Trial)

N/A
Waitlist Available
Led By Denis Blondin
Research Sponsored by Université de Sherbrooke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).
Awards & highlights

GB9 Trial Summary

Activation of Brown Adipose Tissue Metabolism Using Mirabegron

Eligible Conditions
  • Type 2 Diabetes

GB9 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~150 minutes before and mean of time 210 and 270 minutes after drug administration (steady state).
This trial's timeline: 3 weeks for screening, Varies for treatment, and 150 minutes before and mean of time 210 and 270 minutes after drug administration (steady state). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
BAT glucose uptake
Change in activation of Brown Adipose Tissue (BAT) (oxidative metabolism and blood flow)
Secondary outcome measures
BAT lipolysis
Changes in pancreatic and gut hormones
Hepatic Glucose production
+3 more

Side effects data

From 2019 Phase 4 trial • 28 Patients • NCT02086188
7%
urinary tract infection
7%
asthma
7%
gastritis
7%
fatigue
7%
diarrhea
7%
headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Mirabegron

GB9 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Study BExperimental Treatment2 Interventions
Metabolic PET study with mirabegron and bisoprolol
Group II: Study AActive Control1 Intervention
Metabolic PET study with mirabegron
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mirabegron
2008
Completed Phase 4
~18640
Bisoprolol Fumarate
2021
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

Université de SherbrookeLead Sponsor
290 Previous Clinical Trials
68,936 Total Patients Enrolled
Laval UniversityOTHER
417 Previous Clinical Trials
172,263 Total Patients Enrolled
Denis BlondinPrincipal InvestigatorUniversité de Sherbrooke

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Activation of Brown Adipose Tissue Metabolism Using Mirabegron
Denis Blondin 2021. "Activation of Brown Adipose Tissue Metabolism Using Mirabegron". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04823442.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top